464 related articles for article (PubMed ID: 28356155)
1. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
[TBL] [Abstract][Full Text] [Related]
2. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
Queiro R; Cañete JD; Montilla C; Abad MA; Montoro M; Gómez S; Cábez A;
J Rheumatol; 2019 Jul; 46(7):710-715. PubMed ID: 30709957
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
4. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
5. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
Queiro R; Brandy A; Rosado MC; Lorenzo A; Coto P; Carriles C; Alperi M; Ballina J
J Clin Rheumatol; 2018 Oct; 24(7):381-384. PubMed ID: 29509560
[TBL] [Abstract][Full Text] [Related]
6. Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease.
da Cruz Ribeiro E Souza E; da Silva Carneiro SC; Yazbek MA; de Cássia Menin R; Campanholo CB; Carneiro JN; da Silva CHM; Ranza R
Adv Rheumatol; 2020 Sep; 60(1):49. PubMed ID: 32962756
[TBL] [Abstract][Full Text] [Related]
7. Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study.
Queiro R; Cañete JD; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2020 Apr; 22(1):82. PubMed ID: 32295620
[TBL] [Abstract][Full Text] [Related]
8. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM
RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713
[TBL] [Abstract][Full Text] [Related]
10. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
Gossec L; de Wit M; Kiltz U; Braun J; Kalyoncu U; Scrivo R; Maccarone M; Carton L; Otsa K; Sooäär I; Heiberg T; Bertheussen H; Cañete JD; Sánchez Lombarte A; Balanescu A; Dinte A; de Vlam K; Smolen JS; Stamm T; Niedermayer D; Békés G; Veale D; Helliwell P; Parkinson A; Luger T; Kvien TK;
Ann Rheum Dis; 2014 Jun; 73(6):1012-9. PubMed ID: 24790067
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
12. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
Queiro R; Cañete JD
Clin Rheumatol; 2018 Mar; 37(3):661-666. PubMed ID: 29380165
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.
Orbai AM; Perin J; Gorlier C; Coates LC; Kiltz U; Leung YY; Palominos PE; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin S; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; Smolen JS; de Wit M; Gossec L
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1772-1779. PubMed ID: 31609525
[TBL] [Abstract][Full Text] [Related]
14. Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study.
Gratacós J; Pablos JL; de Miguel E; Juanola X; Fernández-Carballido C; Ariza R; Terradas-Montana P; Sastré C; Sanabra C;
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):204-210. PubMed ID: 37061282
[TBL] [Abstract][Full Text] [Related]
15. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
Lubrano E; Perrotta FM; Parsons WJ; Marchesoni A
J Rheumatol; 2015 Dec; 42(12):2332-8. PubMed ID: 26523033
[TBL] [Abstract][Full Text] [Related]
16. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
17. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
[TBL] [Abstract][Full Text] [Related]
18. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
20. A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire.
Johnson K; Ye JY; Chandran V; Gladman DD
Semin Arthritis Rheum; 2019 Oct; 49(2):241-245. PubMed ID: 31101369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
